Hepatic Sirt6 activation abrogates acute liver failure

• Published in: Cell death & disease 2024-04, Vol.15 (4), p.283-283, Article 283
• Main Authors: Luo, Jinque, Liu, Huan, Xu, Yanni, Yu, Nanhui, Steiner, Rebbeca A., Wu, Xiaoqian, Si, Shuyi, Jin, Zheng Gen
• Format: Article
• Language: English
• Subjects: 631/80/82/2344; 692/699/1503/1607/2749; Acetaminophen; Acetaminophen - adverse effects; Acetylcysteine; Animals; Antibodies; Apoptosis; Apoptosis - drug effects; Bile ducts; Biochemistry; Biomedical and Life Sciences; Caspase; Cell Biology; Cell Culture; Detoxification; DNA repair; Hepatocytes - drug effects; Hepatocytes - metabolism; Humans; Immunology; Inflammation; Kinases; Life Sciences; Liver; Liver - drug effects; Liver - metabolism; Liver - pathology; Liver Failure, Acute - chemically induced; Liver Failure, Acute - metabolism; Liver Failure, Acute - pathology; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Molecular modelling; Overdose; Oxidative stress; Oxidative Stress - drug effects; Poly(ADP-ribose) polymerase; Sirtuins - genetics; Sirtuins - metabolism; Transgenic mice
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-024-06537-5

Acute liver failure (ALF) is a deadly illness due to insufficient detoxification in liver induced by drugs, toxins, and other etiologies, and the effective treatment for ALF is very limited. Among the drug-induced ALF, acetaminophen (APAP) overdose is the most common cause. However, the molecular mechanisms underlying APAP hepatoxicity remain incompletely understood. Sirtuin 6 (Sirt6) is a stress responsive protein deacetylase and plays an important role in regulation of DNA repair, genomic stability, oxidative stress, and inflammation. Here, we report that genetic and pharmacological activation of Sirt6 protects against ALF in mice. We first observed that Sirt6 expression was significantly reduced in the liver tissues of human patients with ALF and mice treated with an overdose of APAP. Then we developed an inducible Sirt6 transgenic mice for Cre-mediated overexpression of the human Sirt6 gene in systemic (Sirt6-Tg) and hepatic-specific (Sirt6-HepTg) manners. Both Sirt6-Tg mice and Sirt6-HepTg mice exhibited the significant protection against APAP hepatoxicity. In contrast, hepatic-specific Sirt6 knockout mice exaggerated APAP-induced liver damages. Mechanistically, Sirt6 attenuated APAP-induced hepatocyte necrosis and apoptosis through downregulation of oxidative stress, inflammation, the stress-activated kinase JNK activation, and apoptotic caspase activation. Moreover, Sirt6 negatively modulated the level and activity of poly (ADP-ribose) polymerase 1 (PARP1) in APAP-treated mouse liver tissues. Importantly, the specific Sirt6 activator MDL-800 exhibited better therapeutic potential for APAP hepatoxicity than the current drug acetylcysteine. Furthermore, in the model of bile duct ligation induced ALF, hepatic Sirt6-KO exacerbated, but Sirt6-HepTg mitigated liver damage. Collectively, our results demonstrate that Sirt6 protects against ALF and suggest that targeting Sirt6 activation could be a new therapeutic strategy to alleviate ALF.